Clinical Trial Update: Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, and effects on markers of intravascular inflammation in patients with acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• E5555

Snippet

Sponsor: Eisai Inc. | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED